This document provides an overview of Standard 7 of the National Safety and Quality Health Service Standards, which relates to blood and blood products. It discusses the four criteria of the standard - governance and systems, documenting patient information, managing blood and blood product safety, and communicating with patients. It outlines the requirements under each criterion, such as having policies and procedures, documenting transfusions in patient records, managing storage and transport of blood safely, and providing information to patients. The document emphasizes that the goal of the standard is to establish a quality improvement system focused on appropriate and safe use of blood and blood products.
March 02, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Top seven healthcare outcome measures of healthJosephMtonga1
The seven healthcare outcome measures are meant to understand the quality of health systems and how they could be measured and how quality care could be provided to clients.
A review of the total knee replacement pathway: Integrated care is quality careApollo Hospitals
A Total Knee Replacement (TKR) Pathway (adapted from the Credit Valley Hospital, Canada) is in place at the Apollo Health city facility since 2011. We re-visited the pathway design and the priority grid that led to its adaptation. We analyzed the data with the aim to analyze repetitive and unique trends and evaluate the performance of the pathway. Even with the increased volume the patient satisfaction rose from 56% at the time of pathway implementation to 77% at the end of the evaluation period of 45 months. The Average Length of Stay reduced by 27% from 7.94 to 5.78 days (the difference between the initial and final recorded values), in the same evaluation time period. The methodology of evaluation of the pathway was adapted from the Leuven Clinical Pathway Compass 5 way approach.
Clinical practice guidelines are “systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.”They are intended to offer concise instructions on how to provide healthcare services.The most important benefit of clinical practice guidelines is their potential to improve both the quality or process of care and patient outcomes. Increasingly, clinicians and clinical managers must choose from numerous, sometimes differing, and occasionally contradictory, guidelines.
Patient Blood Management: Impact of Quality Data on Patient OutcomesViewics
Patient blood management (PBM) has been proven to improve patient outcomes and save hospitals millions of dollars. Ensuring the quality of your data is central to decision making and critical to having a strong PBM program.
Would you like to learn how your organization can improve patient outcomes by implementing a PBM program based on accurate data?
If so, view this presentation by blood management expert Lance Trewhella. Lance presents how to develop a successful, evidence-based, multidisciplinary PBM program aimed at optimizing the care of patients who might need transfusion.
You’ll learn:
• Current recommendations for blood transfusion utilization
• The impact of quality data on PBM programs
• Best data practices in PBM
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelLevi Shapiro
Overview of the
- Healthcare ecosystem complexity increasing rapidly
- Pharma industry is facing a crisis: trends shaping the industry
- RWE complements RCTs and captures implementation of innovation
- RWE is one component of the integrated evidence needed for stakeholders
- Integrated Evidence: Optimizing patient access
- Integrated Evidence: Label expansion
- Maximizing the value of data requires a scalable platform and expertise
Introduction of the NZ Health IT Plan enables better gout management - Reflections of an early adopter. Presented by Peter Gow, Counties Manukau DHB, at HINZ 2014, 12 November 2014, 11.37am, Plenary Room
March 02, 2018
Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to controlling runaway health care costs, but are often difficult for health care entities to incorporate into their existing infrastructures. Because value-based health care initiatives have bipartisan support, it is likely that these programs will continue to play a major role in both the public and private health insurance systems. As such, there is a pressing need to evaluate the implementation of these initiatives thus far and to discuss the direction that American health care financing will take in the coming years.
To explore this important issue, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School collaborated with Ropes & Gray LLP to host a one-day conference on value-based health care. This event brought together scholars, health law practitioners, and health care entities to evaluate the impact of value-based health care on the American health care system.
For more information, visit our website at: http://petrieflom.law.harvard.edu/events/details/will-value-based-care-save-the-health-care-system
Top seven healthcare outcome measures of healthJosephMtonga1
The seven healthcare outcome measures are meant to understand the quality of health systems and how they could be measured and how quality care could be provided to clients.
A review of the total knee replacement pathway: Integrated care is quality careApollo Hospitals
A Total Knee Replacement (TKR) Pathway (adapted from the Credit Valley Hospital, Canada) is in place at the Apollo Health city facility since 2011. We re-visited the pathway design and the priority grid that led to its adaptation. We analyzed the data with the aim to analyze repetitive and unique trends and evaluate the performance of the pathway. Even with the increased volume the patient satisfaction rose from 56% at the time of pathway implementation to 77% at the end of the evaluation period of 45 months. The Average Length of Stay reduced by 27% from 7.94 to 5.78 days (the difference between the initial and final recorded values), in the same evaluation time period. The methodology of evaluation of the pathway was adapted from the Leuven Clinical Pathway Compass 5 way approach.
Clinical practice guidelines are “systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances.”They are intended to offer concise instructions on how to provide healthcare services.The most important benefit of clinical practice guidelines is their potential to improve both the quality or process of care and patient outcomes. Increasingly, clinicians and clinical managers must choose from numerous, sometimes differing, and occasionally contradictory, guidelines.
Patient Blood Management: Impact of Quality Data on Patient OutcomesViewics
Patient blood management (PBM) has been proven to improve patient outcomes and save hospitals millions of dollars. Ensuring the quality of your data is central to decision making and critical to having a strong PBM program.
Would you like to learn how your organization can improve patient outcomes by implementing a PBM program based on accurate data?
If so, view this presentation by blood management expert Lance Trewhella. Lance presents how to develop a successful, evidence-based, multidisciplinary PBM program aimed at optimizing the care of patients who might need transfusion.
You’ll learn:
• Current recommendations for blood transfusion utilization
• The impact of quality data on PBM programs
• Best data practices in PBM
What's Next in RWE_Amy Rudolph_Novartis_mHealth IsraelLevi Shapiro
Overview of the
- Healthcare ecosystem complexity increasing rapidly
- Pharma industry is facing a crisis: trends shaping the industry
- RWE complements RCTs and captures implementation of innovation
- RWE is one component of the integrated evidence needed for stakeholders
- Integrated Evidence: Optimizing patient access
- Integrated Evidence: Label expansion
- Maximizing the value of data requires a scalable platform and expertise
Introduction of the NZ Health IT Plan enables better gout management - Reflections of an early adopter. Presented by Peter Gow, Counties Manukau DHB, at HINZ 2014, 12 November 2014, 11.37am, Plenary Room
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Leading the Way in Nephrology: Dr. David Greene's Work with Stem Cells for Ki...Dr. David Greene Arizona
As we watch Dr. Greene's continued efforts and research in Arizona, it's clear that stem cell therapy holds a promising key to unlocking new doors in the treatment of kidney disease. With each study and trial, we step closer to a world where kidney disease is no longer a life sentence but a treatable condition, thanks to pioneers like Dr. David Greene.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
2. Standard 7
Blood and Blood
Products
Standard 10
Preventing Falls and
Harm from Falls
Standard 1
Governance for Safety and
Quality in Health
Service Organisations
Standard 2
Partnering with
Consumers
Standard 4
Medication
Safety
Standard 3
Healthcare
Associated
Infections
Standard 8
Preventing and
Managing Pressure
Injuries
Standard 9
Recognising and
Responding to Clinical
Deterioration in Acute
Health Care
Standard 5
Patient Identification
and Procedure
Matching
Standard 6
Clinical
Handover
Standard 7
Blood and Blood
Products
The NSQHS Standards
3. Inherent risks
Why a blood standard?
Ingrained in the culture of medical practice
Inappropriate transfusions
Product wastage
4. The Blood Standard covers
Use of blood and blood products
The prescribing practice and clinical use of blood
and blood products, and whether or not those
products are prescribed and used appropriately
Management of blood and blood products
Handling, transport, storage (including inventory
management) of blood and blood products
Administration of blood and blood products
The process used to deliver the product to the
patient.
Scope - activities
5. Scope
Blood Biological Medicine
Fresh blood
products eg
• Red cells
• Platelets
• Plasma
• Cryoprecipitate
• Serum eye drops
Plasma derived
products eg
• IVIg
• RhD immunoglobulin
• Clotting factors
• Albumin
• Monoclonal
antibodies
• Vaccines
• Other
recombinant
products
Plasma derived
products eg
• Tisseel
• Artiss
• C1-INH
• Fibrinogen
Recombinant clotting
factors
Classes
of
products
funded
under
National
Blood
Arrangements
Classes
of
products
not
funded
under
National
Blood
Arrangements
Haematopoietic
progenitor cells
Currently covered by Standard 7
Not currently covered by Standard 7
8. Transfusion quality improvement system
(Action 7.4.1)
Improve
quality and
use of
policies
(7.1.3)
Reduce
systems
risks (7.2.2)
Reduce
adverse
event risks
(7.3.1)
Improve
documentatio
n (7.5.3)
Reduce
managemen
t risks
(7.2.2)
Reduce
wastage
(7.8.2)
Improve
provision of
patient
information
(7.10.1)
Reduce
administration
risks (7.6.2)
Improve
documentatio
n of consent
(7.11.1)
9. Oversight of the program
– Review reports
– Identify recurring issues
– Root cause analysis of incidents
– Develop or agree action plan
– Evaluate effectiveness of actions
Transfusion governance
group (Action 7.4.1)
What about in
small organisations?
Join with other hospitals or identify
a group responsible for more than
just transfusion practice (ensuring
they have a clear remit to govern
transfusion practice)
10. You should have policies, procedures and protocols that
reflect best practice, and national evidence based
guidelines where they are available.
Your policies, procedures and protocols should cover
the spectrum of:
– Use of blood and blood products
– Management of blood and blood products
– Administration of blood and blood products
Policies, procedures and
protocols (Action 7.1.1)
13. A best possible history of blood product
usage and relevant clinical and product
information is documented in the patient
clinical record
This action builds on Action 1.9.1 by
identifying the information relevant to
transfusion of blood and blood products that
should be documented
The patient clinical record
(Action 7.5.1)
14. Type of product
Volume of product
Date and time of
commencement
Date and time of completion
Observations
Patient response including
any adverse events
Product identification
Provision of information
Patient consent or refusal
Indications
Special product
requirements
Known patient transfusion
history
Compatibility label or report
Documentation
requirements
15. Patient documentation
case study
What actions are required to demonstrate compliance with
the Standard?
(note that this case study is presented not to demonstrate particular actions that are required to achieve
accreditation, but to demonstrate that the purpose of Standard 7 is to improve safety and quality based on an
assessment of risk).
Hospital One Hospital Two
Has policy Yes Yes
Documentation
completeness
audit results
50% of records
are complete
95% of records
are complete
Documentation
sample results
5% of units fate
not documented
<0.01% of units
fate not
documented
16. Transfusion governance group has reviewed findings and
developed and implemented an action plan
Outcome: the action plan is matched with the level of compliance.
Case Study
Hospital One
Reviewed policy
Implemented training of all staff
Identified staff associated with non-compliance and
communicated directly with them
Made changes to the IT system to facilitate inclusion of
all information (prompts)
Increased frequency of audit on the hospital audit plan
Initiated more regular spot checks of fate of product
against patient records
17. Audit report does not have a management response or action plan
They posted on the intranet a reminder to document transfusion in
the patient clinical record
They have not undertaken any other
follow up and the next audit is scheduled
for one year away
Case Study
Hospital One
Outcome: the action plan is not matched with
the level of compliance. The health service
organisation needs to demonstrate additional
work prior to accreditation.
18. They posted on the intranet a reminder to
document transfusion in the patient clinical
record
They have not undertaken any other follow
up and the next audit is scheduled for one
year away
Outcome: the action plan is matched with the level of
compliance.
Case Study
Hospital Two
19. Recognise and respond to
adverse events
Document adverse events in
the patient clinical record
Take action to reduce the risk
of adverse events as part of
your transfusion quality
improvement system
Managing adverse events
20. 7.6.1
Patient record
Document in patient clinical record
7.6.3
External report
Report to pathology provider, or product
manufacturer
7.3.1
Local report
Report in local incident system and review by
Transfusion Governance Group
7.3.2
Executive report
Review of incident analysis by highest
governance level
7.3.3
State report
Participate in state haemovigilance reporting
7.3.3 National report
Participate in national haemovigilance reporting
Complexities
of
incident
reporting
22. Blood must be stored and handled appropriately to
prevent risk to patients.
Systems should be implemented to reduce risks
associated with receipt, storage, collection, and
transport (Action 7.7.1 and 7.7.2)
Wastage of blood should be minimised (Action 7.8.1
and 7.8.2)
Management of blood
and blood products
23. Many health service organisations receive blood from an
outsourced pathology
It remains the health service organisation’s responsibility to
demonstrate compliance with the Standard
Responsibility where services are outsourced
You use blood
provided by a
contracted pathology
provider
Have a contract that
includes standards
and reporting
Review reports and
seek implementation
of strategies to
rectify problems
25. Develop or identify resources to inform patients and their
carers about the alternatives, risk and benefits of
transfusion (Action 7.9.1)
Provide this information to patients and their carers in a
format that is understood and meaningful (7.10.1)
Allow patients and carers to partner in decisions on their
care based on the communication on the alternatives,
risks and benefits of transfusion (Action 7.9.2)
Communication
(Actions 7.9.1, 7.9.2 and 7.10.1)
26. Have a documented consent policy
Ensure written and documented consent meets local
policy
Ensure the consent is actually informed – link with 7.9
and 7.10
Assess compliance with the consent policy, and take
actions to increase compliance
Consent (Action 7.11.1)
27. When you are developing your consent policy consider….
How long does the
consent last?
Who is documenting
the consent?
Is the consent
specific to
transfusion?
What do you do when a
patient is unable to
consent?
29. Clinical practice guidelines
National Blood Authority www.blood.gov.au/guidelines
Patient Blood Management Guidelines
Module 1: Critical Bleeding Massive Transfusion
Module 2: Perioperative
Module 3: Medical
Module 4: Critical Care
Module 5: Obstetric
Module 6: Paediatric/Neonates
Guidelines on the Prophylactic Use of Rh D Immunoglobulin (anti-D) in Obstetrics
Criteria for the Clinical Use of Intravenous Immunoglobulin (second edition)
NHMRC guidelines portal www.nhmrc.gov.au/guidelines
Factor VIII and FIX Guidelines
Warfarin Reversal Consensus Guidelines
Australian and New Zealand Society of Blood Transfusion (ANZSBT) guidelines and publications
www.anzsbt.org.au/publications/
Available resources
30. Product information and product management
10 Tips to Help Manage you Blood Product Inventory http://www.nba.gov.au/supply/10-tips.pdf
Managing blood and blood product inventory – Guidelines for Australian Health Providers
http://www.nba.gov.au/supply/inventory-guidelines.pdf
Australian Red Cross Blood Service Blood Component Information Circular
http://www.transfusion.com.au/sites/default/files/BCI%202012.pdf
The Australian Red Cross Blood Service blood components and products web site
http://www.transfusion.com.au/blood_products
BloodSafe eLearning Australia module on Transporting Blood https://www.bloodsafelearning.org.au/
ANZSBT Guidelines for the Administration of Blood Products http://www.anzsbt.org.au/publications/
ANZSBT Guidelines for Pre-Transfusion Laboratory Practice http://www.anzsbt.org.au/publications/
National Pathology Accreditation Advisory Council (NPAAC) Requirements for Transfusion Laboratory Practice
http://www.anzsbt.org.au/news/documents/07NPAACReqforTLP.pdf
Australian Standard for Medical Refrigeration Equipment – For the Storage of Blood and Blood Products (AS3864)
http://infostore.saiglobal.com/store/Details.aspx?ProductID=1600490
NBA BloodNet http://www.blood.gov.au/bloodnet/
NBA BloodPortal https://portal.blood.gov.au/
Flippin’ Blood http://www.transfusion.com.au/sites/default/files/Flippin%20Blood%20ONLINE.pdf
Available resources
31. Adverse event recognition and reporting
See Jurisdictional programs
NBA Haemovigilance Reports 2008 http://www.blood.gov.au/haemovigilance/
National Haemovigilance Data Dictionary http://www.blood.gov.au/haemovigilance/
Flippin’ Blood http://www.transfusion.com.au/sites/default/files/Flippin%20Blood%20ONLINE.pdf
ANZSBT Guidelines for the Administration of Blood Products(http://www.anzsbt.org.au/publications/)
Patient information and consent
See Jurisdictional programs
The Australian Red Cross Blood Service – Information for Patients www.mytransfusion.com.au
Jurisdictional Programs
New South Wales – Blood Watch http://www.cec.health.nsw.gov.au/programs/blood-watch
Queensland iBlood Management Program http://www.health.qld.gov.au/qhcss/qbmp/
South Australia – BloodSafe http://www.health.sa.gov.au/bloodsafe/
Victoria – Blood Matters http://www.health.vic.gov.au/bloodmatters/
Western Australia Patient Blood Management Program http://www.health.wa.gov.au/bloodmanagement
Available resources